BioSpace News Archive

BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today that it has filed its Annual Report on Form 10-K for the year ended December 31, 2019 with the U.S. Securities and Exchange Commission. A copy of the annual report is available on BioRestorative Therapies website, www.biorestorative.com, by selecting “Investors” and then “SEC Filings”.

Center for Information and Study on Clinical Research Participation (CISCRP) Announces Second Annual AWARE for All 2021 Virtual Event Series The nonprofit organization aims to boost awareness and interest around clinical trial research through FREE interactive, educational events

BOA Biomedical, a Miraki™ Innovation company, focused on rapidly diagnosing and treating some of the world’s deadliest infectious diseases has announced that the company will begin its First in Human clinical trial for GARNET.

Life Spine Announces FDA 510(k) Clearance for the PROLIFT ® Wedge Expandable Spacer System

Valo Health LLC (Valo), the technology company that is using human-centric data and machine learning computation to transform and accelerate the drug discovery and development process, today announced that David Berry, Ph.D., founder and Chief Executive Officer of Valo will participate in the Credit Suisse Healthcare Innovators Series: The Intersection of Drug Discovery,

ARQ-252 is a potent and highly selective topical JAK1 inhibitor offering potential safety advantages over less selective JAK inhibitors Topline data anticipated second half 2023 Vitiligo affects approximately 1.3 million patients in the U.S.

Ossium Health, a therapeutics company harnessing the power of stem cell science to improve treatment for patients with blood and immune diseases, announced the completion of its $63 million Series B funding round co-led by General Catalyst and Vivo Capital with participation from previous investors First Round Capital, Manta Ray Ventures, and XYZ Capital.

Red Cell Partners, a newly formed investment firm backing disruptive technology-led companies in health care and defense, today announced its launch.

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that it has ordered a new, state-of-the-art, Cosolvent Injection System (CIS) from Vitalis Extraction Technology Inc.

Neon Bloom, Inc. (OTC: NBCO), is proud to announce it has closed on the acquisition of Bazelet Health Systems, Inc.